Guoke Rongzhi (GKRZ) turned a naturally occurring magnetotactic bacterium into an industrial platform — and has spent over a decade proving it out with China's leading disease-control and research institutions.
Beijing Guoke Rongzhi Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to the research, development and production of raw materials, reagents and equipment for the biopharmaceutical sector. Its core technology — biologically derived nanocrystalline magnetic beads (BNCM) — is manufactured using synthetic biology rather than traditional chemical synthesis, giving it a single-crystal, single-magnetic-domain structure at a fixed 50 nm particle size.
The company holds more than 80 authorised patents, including 10+ invention patents, and has undertaken multiple provincial- and ministerial-level key research projects with the Ministry of Science and Technology and the Beijing Municipal Science and Technology Commission. All manufacturing is certified under ISO 9001 and ISO 13485 quality management systems.
GKRZ maintains deep collaborations with authoritative national institutions — including the China CDC, China Customs, BGI Genomics and GenScript Biotech — and led the drafting of China's first industry standard for immuno-magnetic bead enrichment technology. A second production base operates in Leshan, Sichuan, and a group company was established in Shenzhen's Pingshan District in 2021.
These three words, taken directly from GKRZ's own operating principles, shape how the company chooses projects, partners and product priorities.
The world's first biogenic nanocrystalline magnetic bead, developed and scaled through synthetic biology rather than chemical synthesis.
Every raw material advance is developed alongside a real reagent, instrument or clinical collaboration — not left on the lab bench.
Fermentation-based production keeps costs roughly half those of comparable imported beads, without compromising quality.
Patent No. 2016100528793.
Awarded by the Zhongguancun Demonstration Zone Branch Park.
Jointly supported by the Ministry of Science and Technology and the Beijing Municipal Commission of Science and Technology.
Through central state-owned enterprise investment institutions.
Holds a Ph.D. from the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, with over ten years of grassroots experience in China's disease control system, including leadership of multiple key projects funded by the Ministry of Science and Technology and provincial authorities.
GKRZ has been granted over 80 patents, including 10+ invention patents, protecting both its core patented strain and the many downstream applications of BNCM — from raw beads through to finished reagents and instruments.
As the lead drafting entity, GKRZ jointly issued the Technical Specification for Immune Magnetic Bead Enrichment Technology (T/CIQA 60-2023) together with 18 other organisations, including the China Center for Disease Control and Prevention, China Customs, Shenzhen BGI Genomics and Nanjing GenScript Biotech.
We're happy to share detailed technical dossiers, patent lists and clinical collaboration summaries under NDA.
